Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Investigando adaptações metabólicas e psicológicas em um ensaio clínico (IMPACT)

16 de novembro de 2026 atualizado por: Leonard Epstein, State University of New York at Buffalo

Efeito do tempo da refeição e mudanças alimentares nos fatores metabólicos e comportamentais envolvidos no paradoxo da obesidade da insegurança alimentar

This study aims to explore how food insecurity, a lack of consistent access to enough food, may lead to changes in the body that make it harder to lose weight. The investigators are testing whether providing women experiencing food insecurity with a stable, healthy, and personalized meal plan can improve their metabolism and reduce their motivation to eat unhealthy foods. The hypothesis is that addressing food insecurity with a predictable diet can lower a person's respiratory quotient (a measure of how the body uses energy), promote fat burning, and improve overall health. This research will improve the understanding for how food insecurity contributes to obesity and may lead to better solutions for managing weight in individuals facing these challenges.

Visão geral do estudo

Descrição detalhada

Women who experience food insecurity have unpredictable access to food and often miss meals and go hungry, but paradoxically are at a 50% greater risk for developing obesity than women who are food secure. This is due in part to metabolic and behavioral factors involved in food insecurity. Research suggests unpredictable access to food is associated with: 1) a high respiratory quotient (RQ) indicative of substrate oxidation that favors storage of fat and burning of carbohydrates; 2) an increase in fuel efficiency and a reduced thermic effect of food (TEF); 3) higher relative reinforcing efficacy of food (RREFOOD), due in part to periodic food deprivation that results from unpredictable access to food and being hungry, and 4) a short temporal window that involves making decisions that focus on meeting immediate versus long-term goals, as assessed by delay discounting (DD). While people with food insecurity and obesity should modify their diet, an RQ that favors storage of fat coupled with a reduced TEF, high RREFOOD and high DD may compromise the effects of traditional dietary approaches to weight loss. The goal of this pilot study is to examine the effects of providing a personalized, stable, predictable, low carbohydrate, low glycemic index, high protein, low energy dense diet on changes in metabolic and behavioral factors that characterize low-income women with food insecurity who have obesity, using a novel stepped wedge design. This work extends our research on behavioral and metabolic factors involved in food insecurity, and will provide strong pilot data for a randomized, controlled trial of a novel dietary approach that target factors involved in food insecurity and obesity that can improve weight control and reduce cardiometabolic risk factors. The investigators expect to screen at least 60 women, with an estimated screen failure rate of 80%. A goal for this pilot project is to provide effect sizes for future studies. The sample size was determined based on feasibility constraints, with the understanding that these results will serve as pilot data for a larger, fully powered randomized controlled trial.

Tipo de estudo

Intervencional

Inscrição (Real)

12

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • New York
      • Buffalo, New York, Estados Unidos, 14221
        • Farber Hall G56

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Woman between the ages of 18-45.
  • Premenopausal.
  • Obese (BMI ≥ 30).
  • Diagnosed with prediabetes (HbA1c: 5.7%-6.4%).
  • Experiencing food insecurity (score of 2-6 on the six-item food insecurity questionnaire).
  • Income below 300% of the household federal poverty threshold.
  • Lives alone.

Exclusion Criteria:

  • Actively planning to become pregnant (e.g., individuals trying to conceive or undergoing fertility treatment, based on self-report).

  • Delivered a baby within the past 6 months (self-report).

  • Non-ambulatory (e.g., individuals unable to walk independently or requiring a wheelchair for mobility).

  • Intellectual impairment that would impact treatment adherence.

  • Unmanaged mood disorders, substance use disorders, personality disorders, or a history of eating disorders, including:

    • Generalized anxiety disorder.
    • Depression.
    • Alcohol dependence.
    • Schizophrenia.
    • Anorexia nervosa, bulimia, or binge eating disorder within the past 6 months.
  • Recent weight loss exceeding 5% of body weight within the past 6 months (self-report).

  • Food allergies to study-related foods, including dairy, soy, nuts, or gluten.

  • History of bariatric surgery or GLP-1 agonist use (self-report).

  • Inability to read or write in English (self-report).

  • Planned relocation out of the study area during the study timeframe (self-report).

  • Uncontrolled diabetes (HbA1c > 9%) or hypertension (blood pressure > 160/100 mmHg), based on self-report or screening visit measurements.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Control phase

During this phase, participants are told to maintain typical behaviors and not change any normal patterns of activity/eating.

Experimental: Treatment phase

There are two components to the treatment:

Food provisioning: The food provisioning component will consist of bi-weekly home deliveries of three meals a day. The number of calories in the provided meals for each day will be personalized based on each participant's resting metabolic rate. Caloric targets for each participant will be 20% of TDEE as this translates to ~1-2 pounds of weight loss per week. Diets composition will also be tailored to help improve TEF and RQ.

Behavioral Skills Training: This will be based on an evidence-based behavioral weight-loss program developed in our lab. This treatment has shown clinically significant weight loss with positive effects sustained over 10-years. The specific includes lessons on self-monitoring, developing alternatives to foods, meal-planning, goal setting, episodic future thinking, physical activity, and self-reinforcement.

7 sessions including: Hunger and fullness, eating on a budget, traffic light eating plan, menu planning, creating alternatives to food, financial planning, and changing the environment.

3 meals a day consisting of low energy dense, nutrient rich, ready to eat, low GI, foods delivered to the participants' homes.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in body weight
Prazo: Through study completion, an average of 25 weeks

measured in kgs using a weight scale.

Through study completion, an average of 25 weeks
change in HBA1C
Prazo: Through study completion, an average of 25 weeks.

measured via a finger-prick blood sample analyzed using a point-of-care device

Through study completion, an average of 25 weeks.
Change in respiratory quotient
Prazo: Through study completion, an average of 25 weeks.

will be measured in morning fasting state using the Breezing Pro, an FDA approved device for portable metabolic measures

Through study completion, an average of 25 weeks.
change in TEF
Prazo: Through study completion, an average of 25 weeks.

will be measured in morning fasting state using the Breezing Pro, an FDA approved device for portable metabolic measures

Through study completion, an average of 25 weeks.
Change in delay discounting
Prazo: Through study completion, an average of 25 weeks.

will be measured using the adjusting amount delay discounting task that presents participants with choices between a fraction of the total delayed amount of money now or the full amount ($100 &/ $1000) at a future delayed time for five different periods from 30 days, 180 days, 365 days (1 year), 1095 days (3 years), 1825 days (5 years) (order randomized).

Through study completion, an average of 25 weeks.
Change in RRE
Prazo: Through study completion, an average of 25 weeks.

RRE will be assessed through a survey that will use participants' preferred snack foods that are classified as either hyperpalatable or healthy. Scores have no fixed minimum or maximum, as they are determined by the highest ratio completed before the participant stops working for the food reward. Higher scores indicate greater reinforcing efficacy and a stronger motivational drive for the food reward, which is considered a worse outcome in this context.

Through study completion, an average of 25 weeks.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
change in stress
Prazo: Through study completion, an average of 25 weeks.

measured using the Perceived Stress Scale. The Perceived Stress Scale is a validated 10-item questionnaire that measures the perception of stress over the past month. Scores range from 0 to 40, where higher scores indicate greater perceived stress and worse outcomes.

Through study completion, an average of 25 weeks.
change in physical activity
Prazo: Through study completion, an average of 25 weeks.

measured using a Fitbit activity monitor

Through study completion, an average of 25 weeks.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

16 de julho de 2025

Conclusão Primária (Real)

30 de junho de 2026

Conclusão do estudo (Real)

30 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

17 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de janeiro de 2025

Primeira postagem (Real)

30 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de janeiro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The investigators plan to share de-identified individual participant data (IPD) with other researchers to promote transparency, reproducibility, and the advancement of scientific knowledge.

Prazo de Compartilhamento de IPD

The IPD and supporting information (Study Protocol, SAP, ICF, and Analytic Code) will be made available no later than 12 months after the publication of the primary study results or 12 months after the final study completion date (November 1, 2025), whichever comes first. Therefore, the anticipated start date for data availability is November 1, 2026. The IPD and supporting information will remain available for a period of 5 years from the start date, allowing sufficient time for secondary analyses and collaborative research. The anticipated end date is November 1, 2031.

Critérios de acesso de compartilhamento IPD

Qualified Researchers: Access will be granted to researchers affiliated with academic, non-profit, or governmental institutions conducting non-commercial research. Researchers must demonstrate a legitimate scientific purpose for using the data.

Individual Participant Data (IPD):

De-identified data for all primary and secondary outcome measures (e.g., respiratory quotient, thermic effect of food, body weight, relative reinforcing value of food, and delay discounting).

Accompanying metadata and codebooks for proper interpretation of the data.

Supporting Information:

Study Protocol: Detailed description of the study design and methodology. Statistical Analysis Plan (SAP): Comprehensive explanation of the planned statistical analyses for all outcomes.

Informed Consent Form (ICF): Template of the consent form used during the study.

Analytic Code: Scripts used for data cleaning and statistical analyses, enabling reproducibility of results.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever